We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 208

Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • June 17 2013

Although the Court of Appeal had split 2-1, the Supreme Court refused Takeda's application for leave as well as the motion to intervene by Canada's


Patent not eligible for listing: patent claiming one medicinal ingredient,but directed to a fixed-dose combination of medicines
  • Borden Ladner Gervais LLP
  • Canada
  • October 15 2014

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed


Court bifurcates determination of Start Date for section 8 action
  • Borden Ladner Gervais LLP
  • Canada
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex


Order of prohibition granted in respect of one of two asserted patents
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Two patents were under consideration by the Court in this application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations


Teva's allegation for section 8 damages not struck on appeal
  • Borden Ladner Gervais LLP
  • Canada
  • October 28 2013

Pfizer appealed a decision refusing to strike Teva’s Statement of Claim to the Federal Court, but the appeal was dismissed because a de novo review


NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction
  • Borden Ladner Gervais LLP
  • Canada
  • February 13 2013

In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The


Novo Nordisk v. Cobalt
  • Borden Ladner Gervais LLP
  • Canada
  • August 18 2010

The Trial Judge dismissed an application seeking to prohibit Cobalt from coming to market with its generic repaglinide product


Other IP industry news of note
  • Borden Ladner Gervais LLP
  • Canada
  • August 25 2010

The amendments to the Federal Court Rules regarding expert witnesses have been published into law (starting at pg 1547


Astrazeneca v. Apotex
  • Borden Ladner Gervais LLP
  • Canada
  • August 25 2010

The Court found the allegations of invalidity as to lack of sound prediction of utility and of obviousness justified and dismissed the application


Court of Appeal denies patent issuance for obviousness double patenting
  • Borden Ladner Gervais LLP
  • Canada
  • November 3 2010

In an appeal of a decision of the Commissioner of Patents, Bayer challenged the Commissioner’s decision that its patent was not issuable on the basis of obviousness double-patenting